<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092348</url>
  </required_header>
  <id_info>
    <org_study_id>madonna</org_study_id>
    <nct_id>NCT04092348</nct_id>
  </id_info>
  <brief_title>FoxO3a and PU.1 in Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Value of FoxO3a and PU.1 Expression in Pediatric Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Lymphoblastic Leukemia (ALL) is one of the four major types of leukemia which is common
      in both children and adolescents; however, it is the most common pediatric malignancy
      diagnosed in children younger than 20 years .The disease pathogenesis results from blockade
      at any stages of normal lymphoid differentiation with uncontrolled proliferation of lymphoid
      cells. According to the World Health Organization (WHO) definition, ALL is categorized in
      B-Lymphoblastic Leukemia (B-ALL) And T-Lymphoblastic Leukemia (T-ALL), originated from B- and
      T-Lineage lymphoid precursor cells, respectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proto-oncogenes and tumor suppressor genes are the most important genes involved in
      leukemogenesis , which their alterations disrupt normal regulatory processes such as
      self-renewal, proliferation, differentiation and apoptosis in target cells. Among those genes
      FoxO3a gene and PU.1 gene.

      FoxO(Fork head box ,class O) transcription factors function as a tumor suppressor gene and
      are important for stem cell maintenance.They are key regulators of the cellular
      differentiation, growth, survival, cell cycle, metabolism, and cellular stress. There are
      four members of the foxO transcription factors in humans : foxO1, foxO3a, foxO4, foxO6
      .FoxO3a is expressed in various tissues including B - and T-lymphoid cells. Over expression
      of FoxO3a in B and T cell lines induces cell cycle arrest in G1 phase , so it inhibits cell
      proliferation . FoxO3a is an important target of PI3K/AKT signaling pathway,which is
      hyperactivated in various types of cancers .Hyperactivation of this pathway in leukemia leads
      to inactivation of foxO3a in leukemic cells and enhances tumor growth .

      PU .1(Purine-rich box 1) is a member of the E26 transformation-specific (ETS) Family . Normal
      hematopoiesis is securely controlled by asmall number of lineage-specific transcription
      factors, so that the disturbed expression or function of this group may be involved in the
      development of leukemia . PU.1 plays an important role in hematopiotic stem cell (HSC) self
      renewal and in myeloid and B-lymphoid differentiation. It controls the expression of several
      genes involved in hematopoiesis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>FoxO3a and PU.1 levels in acute lymphoblastic leukemia</measure>
    <time_frame>2 years</time_frame>
    <description>detection of the mean difference in FoxO3a and PU.1 expression levels between cases and controls</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <description>children aged 2-17 years and diagnosed as new cases of acute lymphoblastic leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>healthy age- and sex-matched children without ahistory of any malignancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>complete blood count</intervention_name>
    <description>total RNA is isolated from fresh blood samples
RNA is converted into complementary DNA c.DNA
cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene.</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
    <other_name>bone marrow aspirate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  cases

               1. inclusion criteria: children aged 2-17 years and diagnosed as new cases of acute
                  lymphoblastic leukemia

               2. exclusion criteria:

                    1. age more than 17 years

                    2. presence of other hematological disorders, history of other malignancies ,or
                       relapsed ALL

                    3. patients under chemotherapy or radiotherapy

          -  controls (healthy age- and sex-matched children without ahistory of any malignancies)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children aged 2-17 years and diagnosed as new cases of acute lymphoblastic leukemia

        Exclusion Criteria:

          1. age more than 17 years

          2. presence of other hematological disorders, history of other malignancies ,or relapsed
             ALL

          3. patients under chemotherapy or radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rania Mohamed Bakry, Professor</last_name>
    <phone>01221031572</phone>
    <email>Rbakry.md@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dina Ismail El kady, Lecturer</last_name>
    <phone>01118707090</phone>
    <email>Dinaelkady2000@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Ferber EC, Peck B, Delpuech O, Bell GP, East P, Schulze A. FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ. 2012 Jun;19(6):968-79. doi: 10.1038/cdd.2011.179. Epub 2011 Dec 2.</citation>
    <PMID>22139133</PMID>
  </reference>
  <reference>
    <citation>Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013 Jun 1;381(9881):1943-55. doi: 10.1016/S0140-6736(12)62187-4. Epub 2013 Mar 22. Review.</citation>
    <PMID>23523389</PMID>
  </reference>
  <reference>
    <citation>Kerdiles YM, Beisner DR, Tinoco R, Dejean AS, Castrillon DH, DePinho RA, Hedrick SM. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol. 2009 Feb;10(2):176-84. doi: 10.1038/ni.1689. Epub 2009 Jan 11.</citation>
    <PMID>19136962</PMID>
  </reference>
  <reference>
    <citation>Pui CH. Acute lymphoblastic leukemia: introduction. Semin Hematol. 2009 Jan;46(1):1-2. doi: 10.1053/j.seminhematol.2008.09.011.</citation>
    <PMID>19100362</PMID>
  </reference>
  <reference>
    <citation>Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer. 2003 May 1;97(9):2229-35. Erratum in: Cancer. 2993 Aug 1;98(3):659.</citation>
    <PMID>12712476</PMID>
  </reference>
  <reference>
    <citation>Yang XB, Zhao JJ, Huang CY, Wang QJ, Pan K, Wang DD, Pan QZ, Jiang SS, Lv L, Gao X, Chen HW, Yao JY, Zhi M, Xia JC. Decreased expression of the FOXO3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients. PLoS One. 2013 Oct 23;8(10):e78158. doi: 10.1371/journal.pone.0078158. eCollection 2013.</citation>
    <PMID>24194912</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011 Nov;1813(11):1978-86. doi: 10.1016/j.bbamcr.2011.03.010. Epub 2011 Mar 31. Review.</citation>
    <PMID>21440011</PMID>
  </reference>
  <results_reference>
    <citation>Ausserlechner MJ, Salvador C, Deutschmann A, Bodner M, Viola G, Bortolozzi R, Basso G, Hagenbuchner J, Obexer P. Therapy-resistant acute lymphoblastic leukemia (ALL) cells inactivate FOXO3 to escape apoptosis induction by TRAIL and Noxa. Oncotarget. 2013 Jul;4(7):995-1007.</citation>
    <PMID>23828551</PMID>
  </results_reference>
  <results_reference>
    <citation>Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014073. doi: 10.4084/MJHID.2014.073. eCollection 2014. Review.</citation>
    <PMID>25408859</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 14, 2019</study_first_submitted>
  <study_first_submitted_qc>September 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>MRA Youb</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

